Fasting-mimicking diet

01Key questions

02Background and Development

Origin

• Developed by Dr. Valter Longo, director of the USC Longevity Institute
• First published research in 2015 (Brandhorst et al., Cell Metabolism)
• Commercialized as ProLon® (L-Nutra); first FDA-approved "fasting-mimicking" food product

Theoretical Foundation

• FMD triggers fasting metabolic state while providing minimal calories
• Fasting state activates: autophagy, AMPK, sirtuins, stem cell regeneration
• Unlike water fasting: reduced risk, better compliance, gut-sparing

03Uses

Daily Calorie Distribution

Swipe table →

ProLon-Style Menu (Typical)

• Day 1: Nut-based bar, olive oil, soup, supplement packets
• Days 2-5: Reduced portions of nuts, soups, chips, supplement drinks
• Total caloric intake: ~5,500-5,800 kcal over 5 days (~800-1,100 kcal/day)
• Key features: Plant-based, low protein, moderate fat, specific micronutrient formulation

What Makes It "Fasting-Mimicking"

• Extremely low protein (9-10% of calories) — minimizes mTOR activation
• Very low insulin response
• Ketone production begins Day 2-3
• IGF-1 reduction of 30-50%
• Autophagy markers increase

04Clinical Evidence

Key Study Findings

1. Brandhorst et al. 2015 (Cell Metabolism)

• Design: Randomized crossover trial, 100 participants
• Findings:
• Reduced body weight (4.5%), waist circumference
• Lowered blood pressure, IGF-1, C-reactive protein
• Increased stem cell markers
• No serious adverse events

2. Wei et al. 2017 (Science Translational Medicine)

• Design: Clinical trial, various markers
• Findings:
• Reduced metabolic disease risk markers
• Improved insulin sensitivity
• Decreased trunk fat

3. Brandhorst et al. 2024 (Nature Communications) — Biological Age Reduction PMID: 38378685

• Primary findings:
• Median biological age decreased by 2.6 years after 3 FMD cycles (pooled n=86; p<0.001); mean reduction ~1.5 years; modal reduction >3.5 years
• Improvement was independent of weight loss (re-analysis adjusting for BMI change remained significant, p=0.029; second trial p<0.001)
• Hepatic fat fraction reduced ~50% in NAFLD subgroup (14.32% → 7.94%, p=0.02; MRI-measured)
• Visceral adipose tissue (VAT) reduced (p=0.002); subcutaneous adipose tissue (SAT) reduced (p=0.008) — supports FMD's selectivity for visceral fat
• Lymphoid-to-myeloid (L/M) ratio increased (p=0.005) — a reversal of age-related immunosenescence previously shown in mice
• HOMA-IR reduced in pre-diabetics (1.47 → 1.21, p=0.046); HbA1c reduced (5.8 → 5.43, p=0.032)
• Mortality-risk simulation (NHANES-derived):
• 20-year all-cause mortality risk reduced 10.5%
• Heart-disease mortality risk reduced 17.4%
• Cancer mortality risk reduced 6.4%
• Cerebrovascular mortality risk reduced 22%
• Diabetes mortality risk reduced 26%
• Responder caveat: 21–31% of participants showed increased biological age; non-responders had lower baseline CRP and systolic BP, suggesting regression-to-the-mean or acute biomarker fluctuations rather than true worsening.

4. Clinical Nutrition 2025 — Protein Content Trial (randomised parallel-group, healthy adults, n=45)

• Design: Randomised comparison of 7-day FMD with low-protein (LP-FMD) vs high-protein-to-fat-ratio (HP-FMD) vs non-intervention control; matched for carbohydrate content
• Primary outcome: Fasting plasma glucose (reduced similarly in both arms: LP-FMD −10%, HP-FMD −10%, both p<0.05 vs control)
• Mechanistic findings (both FMD arms):
• IGF-1 reduced (−9.0 nmol/L LP-FMD, p<0.0001; −5.4 nmol/L HP-FMD, p=0.024); insulin unchanged
• β-hydroxybutyrate elevated more in LP-FMD (+1.17 mmol/L) than HP-FMD (+0.53 mmol/L, p=0.015)
• Autophagy gene transcripts upregulated — ULK1, BECN1, MAP1LC3A, ATG2A, BNIP3, GABARAPL1, ZFPM1, ATG4B
• Plasma BCAAs increased despite low protein intake — likely marker of tissue autophagy activation
• Differential effects (HP-FMD only):
• Selective visceral fat reduction (not seen with LP-FMD)
• Improved heart-rate variability (RMSSD)
• Improved lipid profile (LDL, HDL)
• Increased gut microbiome diversity
• Interpretation: Total caloric restriction — not protein restriction alone — is the dominant driver of glucose/IGF-1 reduction and autophagy induction. Protein-to-fat ratio modulates body-composition, cardiac-autonomic, lipid, and microbiome outcomes, suggesting FMD can be tailored to individual goals.

Biomarker Changes

Swipe table →

05Applications

1. Longevity / Healthy Aging

• Rationale: FMD cycles may "reset" aging biomarkers
• Protocol: 3-5 day FMD once per quarter
• Evidence: Animal data strong (lifespan extension in mice); human data on biomarkers promising

2. Metabolic Health / Weight Management

• Rationale: Improves insulin sensitivity, reduces visceral fat
• Evidence: Strong clinical data

3. Autoimmune / Inflammatory Conditions

• Rationale: Reduces systemic inflammation; potential for immune reset
• Evidence: Longo lab showed reduced CRP; IBD mouse model data strong
• Applications: Rheumatoid arthritis, multiple sclerosis, IBD

4. Cancer Adjunct Therapy

• Rationale: Fasting sensitizes cancer cells to chemotherapy (differential stress resistance)
• Evidence: Animal data strong; human trials ongoing
• Note: Must be done under oncologist supervision

5. Gut Health

• Rationale: Promotes intestinal stem cell regeneration; reduces gut inflammation
• Evidence: Mouse data shows protection against IBD; human data emerging
• Protocol: 1-2 day FMD monthly for gut health maintenance

06Uses

Commercial

• ProLon®: Original, research-backed, complete meal kit
• Other: Generic FMD recipes available online (less validated)

DIY Approach

• Concept: Replicate macro/calorie profile without commercial product
• Risks: Less precise; less research validation
• If DIYing: Focus on <800 kcal, <10% protein, plant-based

07Comparison: FMD vs Water Fasting

Swipe table →

08Contraindications

Do NOT Use FMD If

• Pregnant or breastfeeding — caloric restriction inappropriate
• Underweight (BMI <18.5) — not appropriate
• Type 1 diabetes — risk of hypoglycemia
• Eating disorder history — may trigger disordered eating
• Active infection — need adequate nutrition
• Children/adolescents — growing bodies need consistent nutrition
• Certain medications — consult provider (especially diabetes medications)

Use With Caution

• Type 2 diabetes — requires medication adjustment
• High stress / HPA axis dysfunction — fasting adds stress
• Athletes in competition — may impair performance

09Side Effects

Generally mild and transient: - Hunger (Day 1-2 most pronounced) - Headache (common; usually resolves) - Fatigue (especially Days 2-3) - Constipation (use caution) - Dizziness (usually mild) - Mood changes (irritability common early)

Note: Most side effects diminish with repeated cycles as body adapts.

102026 Update — Active Trials and New Evidence

Cancer Adjunct Trials (Active as of Sep 2026)

Two phase-2 trials opened in 2026 explicitly test FMD as an adjunct to modern chemo-immunotherapy combinations:

NCT07378306 — FACT-TN (Triple-Negative Breast Cancer)

• Sponsor: Sun Yat-sen University, Guangzhou. Phase 2, single-arm, open-label, n=80. Start: 2026-03-05; Primary completion: 2029-06.
• Population: Operable early or locally advanced TNBC / near-TNBC.
• Rationale: TNBC patients without pathologic complete response (pCR) after neoadjuvant chemo-immunotherapy recur at high rates; FMD's preclinical immunomodulation (anti-tumor immunity activation) provides a mechanistic lever.
• Endpoint: pCR rate and safety.

NCT07500831 — FMD + Toripalimab + Axitinib (Metastatic Renal Cell Carcinoma)

• Sponsor: Qilu Hospital of Shandong University. Single-arm, open-label. Last update posted 2026-03-30; not yet recruiting.
• Population: Metastatic or unresectable clear-cell-predominant RCC, first-line.
• Rationale: IO-TKI is the new first-line standard; preclinical FMD data show synergy with chemo, immunotherapy, and targeted therapy in mice. This is the first trial testing FMD with the modern IO-TKI backbone.

Together: Two oncology indications + two distinct FMD schedules (per-chemo- vs per-IO-TKI-cycle). FACT-TN is the larger, earlier-stage trial; NCT07500831 is the first-line metastatic one. Both will report after 2029.

New Mechanistic / Metabolic Evidence (2025–2026)

• Abdominal adiposity RCT — Clinical Nutrition 2025 (S0939-4753(25)00265-0): A fasting-mimicking diet programme reduces abdominal adiposity in a randomized trial. Reinforces the visceral-fat selectivity noted in the 2025 protein-content study and in the 2024 Brandhorst Nat Commun paper.
• Skeletal muscle preservation — European Journal of Applied Physiology (2022, PMID 35034194): single cycle of FMD does not reduce skeletal muscle function in healthy young adults — addresses the most common clinical objection to periodic fasting.
• Longo 2025 review — Nat Rev Endocrinol 21(2):73-74: positions FMD as a clinically actionable tool for obesity and T2DM, distinct from intermittent fasting protocols.
• DIRECT trial (re-citation) — Nat Commun 2020 (PMID 32576828): FMD + neoadjuvant chemotherapy in HER2-negative breast cancer (BOOG 2014-01, phase 2 RCT). Established feasibility/safety of FMD with chemo; the 2026 FACT-TN trial is its chemo-immunotherapy successor.

Open Mechanistic Questions

• Why 21–31% of participants in the 2024 Brandhorst pooled analysis show increased biological age despite the population mean improvement? The responder-caveat hypothesis (regression-to-the-mean / acute biomarker fluctuations in low-CRP / low-BP non-responders) is plausible but unconfirmed. No 2026 paper has yet re-analyzed this subgroup.
• Whether FMD's effects on lymphoid-to-myeloid ratio (immunosenescence reversal) translate into clinically meaningful infection or vaccine-response outcomes in older adults — the Brandhorst 2024 paper showed the biomarker shift but not its clinical correlate.
• Optimal frequency for chronic use: the 2024 trial used 3–4 monthly ; whether quarterly or twice-yearly is sufficient for biological-age benefit is unknown. The NCT07378306 schedule (every 3 weeks × 8) is for active cancer therapy, not maintenance.

Related: Fasting Protocols | Autophagy | mTOR and AMPK Pathways | Overview - Longevity Science | Metabolic Health and Insulin | NAFLD and Liver Health | Biological Age and Epigenetic Clocks | Senolytics | Rapamycin Dosing Protocols

Further reading: detailed protocols

• FoundMyFitness: fasting topic overview foundmyfitness.com

11Connections

12Sources

1. Brandhorst S et al. (2024). "Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk." Nature Communications . PMID 38378685 -- pooled n=86; median biological age -2.6 yr; weight-loss-independent.PubMed 38378685
2. Brandhorst S et al. (2015). "A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration." Cell Metabolism . PMID 25940989PubMed 25940989
3. Longo VD & Mattson MP. (2014). "Fasting: Molecular Mechanisms and Clinical Applications." Cell Metabolism . PMID 24440038PubMed 24440038
4. NCT07378306NCT07378306
5. NCT07500831NCT07500831
6. PubMed 35034194PubMed 35034194
7. PubMed 32576828PubMed 32576828

13Entry history

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.